Bicara Therapeutics Statistics
Total Valuation
BCAX has a market cap or net worth of $663.00 million. The enterprise value is $174.03 million.
Important Dates
The next estimated earnings date is Friday, May 16, 2025, before market open.
| Earnings Date | May 16, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BCAX has 54.52 million shares outstanding. The number of shares has increased by 2,796.96% in one year.
| Current Share Class | 54.52M |
| Shares Outstanding | 54.52M |
| Shares Change (YoY) | +2,796.96% |
| Shares Change (QoQ) | +399.26% |
| Owned by Insiders (%) | 1.56% |
| Owned by Institutions (%) | 59.30% |
| Float | 28.37M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.35 |
| P/TBV Ratio | 1.35 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 27.93, with a Debt / Equity ratio of 0.00.
| Current Ratio | 27.93 |
| Quick Ratio | 27.22 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -19.14% and return on invested capital (ROIC) is -14.47%.
| Return on Equity (ROE) | -19.14% |
| Return on Assets (ROA) | -13.84% |
| Return on Invested Capital (ROIC) | -14.47% |
| Return on Capital Employed (ROCE) | -16.75% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.24M |
| Employee Count | 55 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, BCAX has paid $187,000 in taxes.
| Income Tax | 187,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 12.78 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 50.98 |
| Average Volume (20 Days) | 516,630 |
Short Selling Information
The latest short interest is 5.31 million, so 9.74% of the outstanding shares have been sold short.
| Short Interest | 5.31M |
| Short Previous Month | 5.05M |
| Short % of Shares Out | 9.74% |
| Short % of Float | 18.71% |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -82.39M |
| Pretax Income | -64.84M |
| Net Income | -68.00M |
| EBITDA | -82.33M |
| EBIT | -82.39M |
| Earnings Per Share (EPS) | -$4.05 |
Full Income StatementBalance Sheet
The company has $489.71 million in cash and $738,000 in debt, giving a net cash position of $488.97 million or $8.97 per share.
| Cash & Cash Equivalents | 489.71M |
| Total Debt | 738,000 |
| Net Cash | 488.97M |
| Net Cash Per Share | $8.97 |
| Equity (Book Value) | 491.88M |
| Book Value Per Share | 9.04 |
| Working Capital | 484.54M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$74.75 million and capital expenditures -$71,000, giving a free cash flow of -$74.82 million.
| Operating Cash Flow | -74.75M |
| Capital Expenditures | -71,000 |
| Free Cash Flow | -74.82M |
| FCF Per Share | -$1.37 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |